The mechanism underlying associations of GIP with lipid metabolism warrants further study, especially in the light of the development of new incretin-based pharmacotherapies for the treatment of obesity, dual GIP and GLP-1 receptor agonists. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.